We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ingenuity Systems Extends Enterprise-Level Software Agreement with GlaxoSmithKline
News

Ingenuity Systems Extends Enterprise-Level Software Agreement with GlaxoSmithKline

Ingenuity Systems Extends Enterprise-Level Software Agreement with GlaxoSmithKline
News

Ingenuity Systems Extends Enterprise-Level Software Agreement with GlaxoSmithKline

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ingenuity Systems Extends Enterprise-Level Software Agreement with GlaxoSmithKline"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ingenuity Systems has announced that they have extended and expanded their existing license agreement with GlaxoSmithKline for access to Ingenuity Pathways Analysis (IPA) software.

The new agreement enables GSK to provide enterprise-wide IPA access to researchers for assessment of the signaling and metabolic pathways, molecular networks, and biological processes that are most significant to disease targets. In addition, GSK will also use Ingenuity's content and proprietary algorithms.

"We are very pleased that GSK will now be able to leverage IPA and other Ingenuity information solutions at the enterprise level," stated Jake Leschly, CEO, Ingenuity Systems.

"Many discovery programs at GSK have already successfully used IPA to understand the complex relationship between pathways and disease. Research teams across the organization will now be able to use these insights to make effective decisions as to which drug targets and compounds to pursue."

Advertisement